Education
About Us
Working with TipRanks
Follow Us
Zynex (ZYXI)
NASDAQ:ZYXI
ZYXI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.66 - $10.62
Previous CloseN/A
Volume7.23K
Average Volume (3M)248.65K
Market Cap
$81.34M
Enterprise Value$541.89M
Total Cash (Recent Filing)$23.85M
Total Debt (Recent Filing)$73.04M
Price to Earnings (P/E)24.1
Beta1.25
Next Earnings
Jul 24, 2025EPS Estimate
-0.2Last Dividend Ex-Date
Jan 05, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding30,238,876
10 Day Avg. Volume361,403
30 Day Avg. Volume248,652
Financial Highlights & Ratios
PEG Ratio4.29
Price to Book (P/B)8.06
Price to Sales (P/S)0.00
P/FCF Ratio40.15
Enterprise Value/Market Cap6.66
Enterprise Value/Revenue0.72
Enterprise Value/Gross Profit4.05
Enterprise Value/Ebitda16.05
Forecast
1Y Price Target
$6.00Price Target Upside123.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Zynex News
PremiumCompany Announcements
Zynex Faces Continued Payment Suspension from Tricare
PremiumCompany Announcements
Zynex Appoints Steven Dyson as New CEO
PremiumCompany Announcements
Zynex Announces Workforce Reduction for Cost Savings
PremiumCompany Announcements
Zynex Elects New Directors at Annual MeetingBulls Say, Bears Say
Bulls Say
LeadershipSteven Dyson, with over 25 years of experience in the medical technology sector, has been appointed as CEO to refocus Zynex's business strategy and return it to a strong growth trajectory.
Market ExpansionZynex is set to expand its payor coverage, which could help mitigate some of the short-term sales decline.
Product DevelopmentZynex has submitted a 510(k) application to the FDA for its NiCO pulse oximeter, which uses precise laser technology for more accurate oxygenation measurement, potentially opening access to a $2.8 billion market.
Bears Say
EarningsNet loss was $10.4M, or ($0.33) per share, more than the estimated loss of $6.3M.
Regulatory RisksRisks include slower-than-anticipated revenue growth due to competition and inability to secure regulatory clearance for other medical devices.
Revenue PerformanceTotal revenue was $26.6M, representing a 43% year-over-year decline and missing the projection of $31.5M.
Ownership Overview
43.17% Insiders
5.94% Mutual Funds
2.70% Other Institutional Investors
42.61% Public Companies and Individual Investors
ZYXI FAQ
What was Zynex’s price range in the past 12 months?
Zynex lowest stock price was $1.66 and its highest was $10.62 in the past 12 months.
What is Zynex’s market cap?
Zynex’s market cap is $81.34M.
When is Zynex’s upcoming earnings report date?
Zynex’s upcoming earnings report date is Jul 24, 2025 which is in 19 days.
How were Zynex’s earnings last quarter?
Zynex released its earnings results on Apr 29, 2025. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of -$0.24 by -$0.09.
Is Zynex overvalued?
According to Wall Street analysts Zynex’s price is currently Undervalued.
Does Zynex pay dividends?
Zynex pays a Notavailable dividend of $0.091 which represents an annual dividend yield of N/A. See more information on Zynex dividends here
What is Zynex’s EPS estimate?
Zynex’s EPS estimate is -0.2.
How many shares outstanding does Zynex have?
Zynex has 30,238,876 shares outstanding.
What happened to Zynex’s price movement after its last earnings report?
Zynex reported an EPS of -$0.33 in its last earnings report, missing expectations of -$0.24. Following the earnings report the stock price went down -25.561%.
Which hedge fund is a major shareholder of Zynex?
Currently, no hedge funds are holding shares in ZYXI
Zynex Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (123.05% Upside)
$6.00 (123.05% Upside)
Blogger Sentiment
Bullish
ZYXI Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 760.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.34%
12-Months-Change
Fundamentals
Return on Equity
-27.52%
Trailing 12-Months
Asset Growth
-16.21%
Trailing 12-Months
Company Description
Zynex
Zynex, Inc. (ZYXI) is a medical technology company that specializes in the design, manufacture, and marketing of medical devices for pain management and rehabilitation. The company operates primarily in the healthcare sector, offering a portfolio of non-invasive electrotherapy products and medical bracing devices aimed at treating chronic and acute pain. With a focus on improving patient outcomes and quality of life, Zynex serves healthcare providers, clinics, and patients across the United States.
ZYXI Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Negative
The earnings call presented a mix of positive developments such as the FDA submission for the NiCO pulse oximeter and cost reduction initiatives, but these were overshadowed by significant revenue decline, increased net loss, and uncertainty regarding the TriCare payment suspension, leading to a challenging financial outlook.Read More>ZYXI Stock 12 Month Forecast
Average Price Target
$6.00
▲(123.05%Upside)
Technical Analysis
Henry Schein
―
Owens & Minor
―
Prestige Consumer Healthcare
―
Guardian Pharmacy Services, Inc. Class A
―